Skip to main content
Fig. 2 | BMC Biology

Fig. 2

From: Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1

Fig. 2

Screening the potential targets of BBR via SPR-LC-MS/MS approach. a The schematic generation of SPR-LC-MS/MS approach. BBR is immobilized on a sensor chip and incubated with the cell lysates from RPMI-8266 and MM.1S cells, followed by SPR analysis. The potential targets of BBR from BBR-protein mixtures were screened and ranked by mass spectrometry analysis. b Venn diagram showing 81 proteins commonly identified in MM cells by SPR-LC-MS/MS approach. A total of 88 and 87 proteins were identified from MM.1S and RPMI-8266 cells in the mass spectrometry analysis, respectively. c Forty-eight potential targets of BBR are shown in the relative quantity heatmap by using a score value cutoff > 700. d Prognostic value of UHRF1 mRNA levels in terms of overall survival in newly diagnosed patients from the UAMS TT2 (n = 256) and UAMS TT3 (n = 158) cohorts. Maxstat analysis was used to calculate the optimal separation of patients based on a cutoff value. e UHRF1 expression in MM primary tumor cells and normal hPBMCs. Normal hPBMCs and MM primary tumor cells were separated using Ficoll-paque density sedimentation. Cells lysates were harvested and subjected to western blotting with anti-UHRF1 and anti-GAPDH antibodies

Back to article page